Have a feature idea you'd love to see implemented?
Let us know!
VTYX Ventyx Biosciences Inc
Price (delayed)
$1.73
Market cap
$122.33M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.36
Enterprise value
$70.63M
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2
Highlights
VTYX's quick ratio has surged by 95% year-on-year and by 69% since the previous quarter
Ventyx Biosciences's EPS has increased by 25% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of VTYX
Market
Valuations
Earnings
Shares outstanding
70.71M
Market cap
$122.33M
Enterprise value
$70.63M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$152.52M
EBITDA
-$151.09M
Free cash flow
-$159.73M
Per share
Balance sheet
Liquidity
EPS
-$2.36
Free cash flow per share
-$2.26
Book value per share
$3.94
Revenue per share
$0
TBVPS
$4.26
Total assets
$301.1M
Total liabilities
$22.33M
Debt
$11.04M
Equity
$278.77M
Working capital
$277.11M
Debt to equity
0.04
Current ratio
23.52
Quick ratio
22.42
Net debt/EBITDA
0.34
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-50%
Return on equity
-54.9%
Return on invested capital
-67.9%
Return on capital employed
-52.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTYX stock price
How has the Ventyx Biosciences stock price performed over time
Intraday
0.58%
1 week
-12.18%
1 month
-27.62%
1 year
-25.75%
YTD
-29.96%
QTD
-20.64%
Financial performance
How have Ventyx Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$166.38M
Net income
-$152.52M
Gross margin
N/A
Net margin
N/A
VTYX's net income is up by 16% year-on-year and by 11% since the previous quarter
The operating income is up by 15% year-on-year and by 10% since the previous quarter
Growth
What is Ventyx Biosciences's growth rate over time
Valuation
What is Ventyx Biosciences stock price valuation
P/E
N/A
P/B
0.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Ventyx Biosciences's EPS has increased by 25% YoY and by 15% from the previous quarter
The price to book (P/B) is 37% lower than the last 4 quarters average of 0.7
Efficiency
How efficient is Ventyx Biosciences business performance
Ventyx Biosciences's ROE has increased by 11% from the previous quarter
The company's return on invested capital rose by 10% QoQ but it fell by 6% YoY
The company's return on assets rose by 9% QoQ
Dividends
What is VTYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTYX.
Financial health
How did Ventyx Biosciences financials performed over time
Ventyx Biosciences's current ratio has soared by 100% YoY and by 66% from the previous quarter
VTYX's quick ratio has surged by 95% year-on-year and by 69% since the previous quarter
The debt is 96% smaller than the equity
The debt is down by 11% year-on-year and by 2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.